You are here: Industry Insights > apixaban

News List

Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban Drugs
December 07, 2021
For patients with venous thromboembolism (VTE), new users of apixaban have lower rates of recurrent VTE and bleeding compared with new users of rivaroxaban, according to a study published online Dec. 7 in the Annals of Internal Medicine.
NICE backs restricted use of Ondexxya pharmatimes
April 07, 2021
NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the ...
NICE backs Portola's Ondexxya pharmatimes
September 14, 2020
The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
How was the Small Molecule Apixaban with Annual Sales of Nearly USD10 Billion “Tempered”? PharmaSources/Yuntian
July 18, 2019
As an oral, direct coagulation factor Xa inhibitor developed by BMS and Pfizer, Eliquis (apixaban) was first approved fo
A Review of U.S. ANDA Approvals Received by Chinese Pharmaceutical Enterprises in the First Half of 2019 PharmaSources/Caicai
July 16, 2019
41 Approval Numbers, Multiple Blockbuster Varieties
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy drugs
December 17, 2018
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo.....